Receptor conversion in distant breast cancer metastases: A Systematic Review and Meta-analysis

Abstract

Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HER2)-targeted therapy decision-making is still largely based on tissue characteristics of the primary tumor. However, a change of estrogen receptor alpha (ERa), progesterone receptor (PR), and HER2 status in distant metastases has frequently been reported. The actual incidence of this phenomenon has been debated. Methods: We performed a meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases. We noted the direction of change (positive to negative or vice versa) and performed subgroup analyses for different thresholds for positivity, the type of test used to assess HER2 receptor status, and metastasis location-specific differences (two-sided tests). Results: Overall, the incidence of receptor conversion varied largely between studies. For ERa, PR, and HER2, we found that random effects pooled positive to negative conversion percentages of 22.5% (95% confidence interval [CI] ¼ 16.4% to 30.0%), 49.4% (95% CI ¼ 40.5% to 58.2%), and 21.3% (95% CI ¼ 14.3% to 30.5%), respectively. Negative to positive conversion percentages were 21.5% (95% CI ¼ 18.1% to 25.5%), 15.9% (95% CI ¼ 11.3% to 22.0%), and 9.5% (95% CI ¼ 7.4% to 12.1%). Furthermore, ERa discordance was statistically significantly higher in the central nervous system and bone compared with liver metastases (20.8%, 95% CI ¼ 15.0% to 28.0%, and 29.3%, 95% CI ¼ 13.0% to 53.5%, vs 14.3%, 95% CI ¼ 11.3% to 18.1, P ¼ .008 and P < .001, respectively), and PR discordance was higher in bone (42.7%, 95% CI ¼ 35.1% to 50.6%, P < .001) and liver metastases (47.0%, 95% CI ¼ 41.0% to 53.0%, P < .001) compared with central nervous system metastases (23.3%, 95% CI ¼ 16.0% to 32.6%). Conclusions: Receptor conversion for ERa, PR, and HER2 occurs frequently in the course of disease progression in breast cancer. Large prospective studies assessing the impact of receptor conversion on treatment efficacy and survival are needed. Meanwhile, reassessing receptor status in metastases is strongly encouraged.